Clinical trials that involve a procedure in which the patient receives bone marrow or stem cells from a donor to treat a number of different blood and bone marrow cancers
If you would like to be considered for a clinical trial you will require a referral from your current treating team.
Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Business hours, Mon to Friday between 9am - 2pm
Trial ID
ACTRN12619000556145
Cancer type
Acute myeloid leukaemia or myelodysplastic syndromes
Status
Open and recruiting
Phase
One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.
Brief summary
A clinical trial to test the safety and effectiveness of the new treatment Lenalidomide in patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome who have been treated with a stem cell or bone marrow transplant. The aim of the clinical trial is to test if Lenalidomide can stop cancer from returning.
Lenalidomide is a type of treatment called immunomodulatory, which works by changing the environment that the cancer cells live in, making it hostile to their survival. Recent clinical trials have shown that Lenalidomide is successful in treating AML and MDS, as well as other types of blood cancer. Lenalidomide is an oral tablet, taken by mouth for up to 48 weeks.
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Trial ID
ACTRN12618000505202
Cancer type
Acute leukaemia and myelodysplasia (MDS)
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Brief summary
A clinical trial to test if the treatment combination cyclosporin and post-transplant cyclophosphamide is better than the standard treatment given for acute leukaemia and myelodysplasia cancer to prevent graft-versus-host disease (GVHD).
The treating doctor has recommended allogeneic stem cell transplant, where stem cells given use the donor’s (sibling) immune system to destroy cancer cells. A complication of allogeneic stem cell transplant is GVHD, where the donor’s immune cells do not recognise the recipient’s body as foreign and attack the body (similar to when the immune system fights a virus / infection). The standard treatment given to prevent GVHD is the combination of cyclosporin and methotrexate (chemotherapy treatment) given following transplant. Cyclosporin is taken orally and cyclophosphamide is given as an infusion into the vein.
Patients will be randomly selected to receive one of the following treatment combinations:
Arm A: Cyclosporin and post-transplant cyclophosphamide
Arm B: Post-transplant cyclosporin and methotrexate
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.